ALNY

#340
Alnylam Pharmaceuticals, Inc.
340.41 USD
+2.23%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
335.16
340.48
년간 변동
225.84
495.55
일일 변동
+2.23%
월간 변동
+9.38%
6달 변화
-27.45%
년간 변동율
+41.92%
이전 종가
333.00
Open
335.23
Bid
Ask
Low
335.16
High
340.48
양
556
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 45.15 B
  • Employee 2 500
  • Founded 2002
  • CEO Yvonne Greenstreet
  • Website www.alnylam.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BFGNJ5
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
170.67
Price to sales ratio
14.42

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

뉴스